Document is current
Any future updates will be listed below
-
Authors
Ganz, Patricia A. http://orcid.org/0000-0002-1841-4143
Cecchini, Reena S. http://orcid.org/0000-0002-9075-9357
Fehrenbacher, Louis
Geyer, Charles E. Jr http://orcid.org/0000-0002-2379-5702
Rastogi, Priya
Crown, John P.
Thirlwell, Michael P. http://orcid.org/0000-0002-7412-4642
Ellison, David M.
Boileau, Jean-Francois
Flynn, Patrick J.
Jeong, Jong-Hyeon
Mamounas, Eleftherios P.
Wolmark, Norman
- License Information
-
More Information
Article History
Received: 29 October 2020
Accepted: 19 April 2021
First Online: 20 May 2021
Competing interests
: J.F.B.: Jewish General Hospital/Segal Cancer Centre receives funding for research from Roche – JF Boileau, PI; Consultant for Roche; participated on Advisory Boards for Roche. J.P.C.: Research funding (to institution): Eisai, Puma Biotechnology, Roche, Boehringer Ingelheim; Employment: OncoMark, Ltd.; Honoraria: Eisai, Puma Biotechnology; MSD Oncology, Pfizer, G1 Therapeutics; Novartis; Speaker’s Bureau: Boehringer Ingelheim, Genomic Health, Roche, Pfizer; Shares: OncoMark Ltd; Travel and accommodation expenses: Pfizer, MSD, Abbvie, Astrazeneca, Novartis. P.A.G.: member of the Breast Cancer Research Foundation scientific advisory board. E.P.M.: Consultant: Genentech/Roche, Exact Sciences, Daiichi Sankyo, Biotheranostics, Puma Biotechnology, Merk; Speaker’s Bureau: Genentech/Roche, Exact Sciences. P.R.: Travel and accommodations, Genentech/Roche, AstraZeneca, and Lilly. N.W.: Research Funding to institution: AstraZeneca/MedImmune (Inst), NSABP Foundation (Inst). All remaining authors declare no competing interests.
: Written informed consent was required for participation.
